Search Results for "Caldolor"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Caldolor. Results 1 to 7 of 7 total matches.
See also: ibuprofen
Intravenous Ibuprofen (Caldolor)
The Medical Letter on Drugs and Therapeutics • Jan 11, 2010 (Issue 1329)
Intravenous Ibuprofen (Caldolor) ...
An intraveneous (IV) formulation of ibuprofen (Caldolor - Cumberland) was recently approved by the FDA for use in adults. It can be administered alone for treatment of mild to moderate pain or as an adjunct to opioid analgesics for moderate to severe pain. It is also approved for reduction of fever.
Intravenous Acetaminophen (Ofirmev)
The Medical Letter on Drugs and Therapeutics • Apr 04, 2011 (Issue 1361)
patients.1
IV ibuprofen (Caldolor), which is approved by the
FDA for use in adults, is marketed ...
The FDA has approved an intravenous (IV) formulation
of acetaminophen (Ofirmev – Cadence) for use in
patients ≥2 years old for management of pain either as
monotherapy (mild to moderate pain) or with an opioid
(moderate to severe pain) and for reduction of fever.
Intravenous Acetaminophen/Ibuprofen (Combogesic IV)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
ibuprofen
(Caldolor) and acetaminophen have been available in
the US for years.1,2
NONOPIOIDS FOR PAIN ...
The FDA has approved Combogesic IV (Hikma), an IV
solution containing acetaminophen and ibuprofen, to
treat mild to moderate pain (alone) or moderate to
severe pain (in combination with an opioid) in adults
when IV analgesia is considered clinically necessary.
Single-drug IV solutions containing ibuprofen
(Caldolor) and acetaminophen have been available in
the US for years.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):68-9 doi:10.58347/tml.2024.1701c | Show Introduction Hide Introduction
Intravenous Diclofenac (Dyloject)
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015 (Issue 1484)
of ketorolac and ibuprofen
(Caldolor)2 are approved for treatment of pain; IV
ibuprofen must be infused over ...
The FDA has approved Dyloject (Hospira), an IV
formulation of the NSAID diclofenac sodium, for use
in adults. It can be administered alone for treatment
of mild to moderate pain or in combination with opioid
analgesics for moderate to severe pain. Dyloject is the
first injectable formulation of diclofenac to become
available in the US.
IV Meloxicam (Anjeso) for Pain
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
of ketorolac,
ibuprofen (Caldolor), and acetaminophen (Ofirmev)
are also available for treatment of pain ...
The FDA has approved Anjeso (Baudax Bio), an IV
formulation of the nonsteroidal anti-inflammatory
drug (NSAID) meloxicam, for once-daily treatment
of moderate to severe pain in adults. Oral meloxicam
(Mobic, and others), which is only indicated
for treatment of chronic pain associated with
osteoarthritis or rheumatoid arthritis, has been
available for 20 years. IV formulations of ketorolac,
ibuprofen (Caldolor), and acetaminophen (Ofirmev)
are also available for treatment of pain.
Comparison Table: Some Nonopioid Analgesics for Pain (online only)
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
) FDA-approved only for use in OA and RA 8.00
Ibuprofen – generic
Caldolor (Cumberland)
400, 600, 800 ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
aspirin or acetaminophen;
400 mg comparable to
acetaminophen/codeine
Caldolor (Cumberland) 100 mg/mL IV ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.